Irrelevance of explicit cost-effectiveness thresholds when coverage decisions can be reversed

Author： Basu Anirban  

Publisher： Informa Healthcare

ISSN： 1473-7167

Source： Expert Review of Pharmacoeconomics and Outcomes Research, Vol.13, Iss.2, 2013-04, pp. : 163-165

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Economic Evaluation and Cost-Effectiveness Thresholds: Signals to Firms and Implications for R&D Investment and Innovation

By Vernon John A.  

PharmacoEconomics, Vol. 27, Iss. 10, 2009-10 ,pp. : 797-806

Adis International

Access to resources Recommend Favorite

Quantification of the Potential Impact of Cost-effectiveness Thresholds on Dutch Drug Expenditures Using Retrospective Analysis

By Boersma Cornelis   Broere Adriaan   Postma Maarten J.  

Value in Health, Vol. 13, Iss. 6, 2010-09 ,pp. : 853-856

Blackwell Publishing

Access to resources Recommend Favorite

The Analysis of Multinational Cost-Effectiveness Data for Reimbursement Decisions: A Critical Appraisal of Recent Methodological Developments

By Manca Andrea   Sculpher Mark J.   Goeree Ron  

PharmacoEconomics, Vol. 28, Iss. 12, 2010-12 ,pp. : 1079-1096

Adis International

Access to resources Recommend Favorite

Cost–effectiveness analysis in pharmacogenomics

By Payne Katherine   Shabaruddin Fatiha H  

Pharmacogenomics, Vol. 11, Iss. 5, 2010-05 ,pp. : 643-646

Future Medicine

Access to resources Recommend Favorite

How Do Cost-Effectiveness Analyses Inform Reimbursement Decisions for Oncology Medicines in Canada? The Example of Sunitinib for First-Line Treatment of Metastatic Renal Cell Carcinoma

By Chabot Isabelle   Rocchi Angela  

Value in Health, Vol. 13, Iss. 6, 2010-09 ,pp. : 837-845

Blackwell Publishing

Access to resources Recommend Favorite